United Capital Financial Advisers LLC grew its position in shares of Sanofi SA (NYSE:SNY) by 15.2% in the second quarter, according to its most recent filing with the SEC. The fund owned 48,558 shares of the company’s stock after acquiring an additional 6,406 shares during the quarter. United Capital Financial Advisers LLC’s holdings in Sanofi were worth $2,101,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Ibex Wealth Advisors purchased a new stake in Sanofi during the 2nd quarter valued at $25,000. Heritage Wealth Advisors raised its holdings in Sanofi by 141.2% during the 2nd quarter. Heritage Wealth Advisors now owns 603 shares of the company’s stock valued at $26,000 after buying an additional 353 shares during the period. Bessemer Group Inc. raised its holdings in Sanofi by 292.4% during the 2nd quarter. Bessemer Group Inc. now owns 671 shares of the company’s stock valued at $29,000 after buying an additional 500 shares during the period. Evolution Wealth Advisors LLC purchased a new stake in Sanofi during the 2nd quarter valued at $40,000. Finally, Massey Quick Simon & CO. LLC purchased a new stake in Sanofi during the 2nd quarter valued at $43,000. Hedge funds and other institutional investors own 7.04% of the company’s stock.
SNY stock traded up $0.61 during midday trading on Thursday, reaching $45.02. The company’s stock had a trading volume of 72,378 shares, compared to its average volume of 1,249,032. The company has a debt-to-equity ratio of 0.40, a quick ratio of 0.85 and a current ratio of 1.22. The stock has a fifty day simple moving average of $42.76 and a two-hundred day simple moving average of $42.79. Sanofi SA has a 1 year low of $40.00 and a 1 year high of $45.62. The firm has a market capitalization of $111.79 billion, a price-to-earnings ratio of 14.37, a PEG ratio of 2.41 and a beta of 0.67.
In other Sanofi news, major shareholder Sanofi sold 172,904 shares of the stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $281.15, for a total value of $48,611,959.60. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 1.00% of the company’s stock.
Several analysts recently weighed in on the company. Sanford C. Bernstein assumed coverage on Sanofi in a report on Tuesday, September 3rd. They set an “outperform” rating and a $52.00 price target on the stock. Jefferies Financial Group restated a “buy” rating on shares of Sanofi in a report on Thursday, August 29th. Zacks Investment Research upgraded Sanofi from a “hold” rating to a “buy” rating and set a $47.00 price target on the stock in a report on Thursday, August 29th. JPMorgan Chase & Co. restated a “neutral” rating on shares of Sanofi in a report on Tuesday, August 6th. Finally, UBS Group upgraded Sanofi from a “neutral” rating to a “buy” rating in a report on Wednesday, August 14th. Six research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $49.67.
Sanofi Company Profile
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Recommended Story: The risks of owning bonds
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.